We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Algernon

News List

Algernon to drop Phase III trial of Ifenprodil for Covid-19 pharmaceutical-technology
July 07, 2021
Algernon Pharmaceuticals has plans not to progress the development of its drug candidate, Ifenprodil, into a Phase III clinical trial for Covid-19.
Algernon’s Ifenprodil lowers interleukin 6 in Phase IIb/III Covid-19 trial pharmaceutical-technology
May 13, 2021
Algernon Pharmaceuticals has reported that NP-120 (Ifenprodil) statistical significantly lowered interleukin 6 (IL-6) in its Phase IIb/III trial to treat Covid-19.
Algernon submits IND application with FDA for possible Covid-19 treatment pharmaceutical-business-review
May 27, 2020
Algernon Pharmaceuticals has completed the submission of an investigational new drug (IND) application to the US Food and Drug Administration (FDA) to assess the Ifenprodil in the phase 2b/3 clinical study to treat Covid-19 patients.